Дата:	--/--/-- --:--:--
Id события:	E5KVF4DES
Тип действия:	ACQUISITION
Статус действия:	ANNOUNCED
Символ покупателя:
Целевой символ:	CNTA
Обновлено:	--/--/-- --:--:--
Цена покупки за акцию:	38
Цена за акцию в валюте:	USD
Ссылки на новости:	https://www.prnewswire.com/news-releases/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders-302729846.html

Action Notes

Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, today announced a definitive agreement for Lilly to acquire Centessa. Under the terms of the transaction agreement, Lilly will acquire all of the issued and to be issued share capital of Centessa (including the American Depositary Shares (ADSs) representing ordinary shares) for $38.00 in cash per share . The transaction, which will be effectuated by way of a scheme of arrangement under the laws of England and Wales, is expected to close in the third quarter, subject to approval by Centessa shareholders, sanction by the High Court of Justice of England and Wales and satisfaction of other customary closing conditions, including regulatory approvals.CNTA special meeting to vote on merger will be held 6/12/2026.